Linadex Drug Interactions

Erythropoietic agents, or other agents that may increase the risk of thrombosis, such as hormone replacement therapy, should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone.
Oral contraceptives: No interaction study has been performed with oral contraceptives. Lenalidomide is not an enzyme inducer. In an in vitro study with human hepatocytes, lenalidomide, at various concentrations tested did not induce CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4/5. Therefore, induction leading to reduced efficacy of medicinal products, including hormonal contraceptives, is not expected if lenalidomide is administered alone. However, dexamethasone is known to be a weak to moderate inducer of CYP3A4 and is likely to also affect other enzymes as well as transporters. It may not be excluded that the efficacy of oral contraceptives may be reduced during treatment. Effective measures to avoid pregnancy must be taken.
Warfarin: Co-administration of multiple 10 mg doses of Lenalidomide had no effect on the single dose pharmacokinetics of R- and S- warfarin. Co-administration of a single 25 mg dose of Warfarin had no effect on the pharmacokinetics of Lenalidomide. However, it is not known whether there is an interaction during clinical use (concomitant treatment with Dexamethasone). Dexamethasone is a weak to moderate enzyme inducer and its effect on Warfarin is unknown. Close monitoring of Warfarin concentration is advised during the treatment.
Digoxin: Concomitant administration with Lenalidomide 10 mg once daily increased the plasma exposure of digoxin. It is not known whether the effect will be different in the use (higher Lenalidomide doses and concomitant treatment with Dexamethasone). Therefore, monitoring of the Digoxin concentration is advised during Lenalidomide treatment.
Statins: There is an increased risk of rhabdomyolysis when statins are administered with Lenalidomide, which may be simply additive. Enhanced clinical and laboratory monitoring is warranted notably during the first weeks of treatment.
Dexamethasone: Co-administration of single or multiple doses of Dexamethasone (40 mg/once daily) has no clinically relevant effect on the multiple dose pharmacokinetics of Lenalidomide (25 mg/once daily).
Interactions with P-glycoprotein (P-gp) inhibitors: In vitro, Lenalidomide is a substrate of P-gp, but is not a P-gp inhibitor. Co-administration of multiple doses of the strong P-gp inhibitor Quinidine (600 mg, twice daily) or the moderate P-gp inhibitor/substrate Temsirolimus (25 mg) has no clinically relevant effect on the pharmacokinetics of Lenalidomide (25 mg). Co-administration of Lenalidomide does not alter the pharmacokinetics of Temsirolimus.